AML 2021: Strategies for Attack Before Diagnosis and After Remission – Module 2

CME: 1.0

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Program Overview

This activity provides an overview of important genetic mutations in acute myeloid leukemia and recent therapeutic advances.

Learning Objective

Upon completion of this activity, participants should be better able to:

  • Identify the impact of minimal residual disease (MRD) analysis and pre-leukemic clones on the treatment of acute leukemia

Post a comment to this article